匹伐他汀在老年动脉粥样硬化性心血管疾病中的应用探讨

摘要/Abstract

摘要： 目的探讨在老年动脉粥样硬化性心血管疾病（ASCVD）患者中匹伐他汀的应用价值。方法选择2018年6月至2020年1月到奉城医院心内科门诊就诊或住院确诊ASCVD的患者412例。随机数字法分为实验组（206例）和对照组（206例）,分别应用阿托伐他汀20mg或匹伐他汀2mg,比较3个月后的两组患者LDL-C水平及达标率,探求理想的用药方法。结果治疗后两组患者的低密度脂蛋白胆固醇（LDL-C）、三酰甘油（TG）、总胆固醇（TC）水平均有明显下降（P<0.05）。以LDL-C 1.8mmol/L为调脂目标值,基线较高不能达到目标值者至少降低50%,对照组：LDL-C降幅为33.2%,达标率为37.38%;实验组：LDL-C降幅为44.8%,达标率为54.37%（P<0.05)。结论老年ASCVD患者的血脂水平偏高,中低强度的他汀类药物能有效降低LDL-C水平,但达标率偏低。LDL-C水平在老年ASCVD患者中达标,需服用较大剂量的他汀类药物。匹伐他汀是一种较新型合成药物,具有降脂效果佳、不良反应少、安全性好等特点,更适合老年患者服用。

关键词: 动脉粥样硬化性心血管疾病, 匹伐他汀, 低密度脂蛋白胆固醇, 老年

邓建新. 匹伐他汀在老年动脉粥样硬化性心血管疾病中的应用探讨[J]. 心血管病防治知识, 2021, 11(4): 32-35.

参考文献

[1] 莫永珍,应对老龄化趋势,发展老年护理技术的点、线、面[J].实用老年医学,2021,35(1):1-2.
[2] 豆小红,新时代要着力构建健康老龄化社会[J].中国人口报,2020-02-06(3).
[3] 杨丽娟. 上海部分中青年体检人群ASCVD发病风险评估[J].中国社区医师,2019,35(21):88-90.
[4] Elmowafye M,Ibrahim HM,Ahmed MA,et al.Atorvastatin-loaded nanostructured lipid arriers(NLCs):strategyto overcome oral delivery drawbacks[J].Drug Deliv,2017,24(1):932-941.
[5] 康晨瑜,王以新,冯妍,等.阿托伐他汀与匹伐他汀调脂机制对比的研究进展[J].中国全科医生,2020,23(14):1722-1728.
[6] Ference BA, Ginsberg HN, Graham I, et al.Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel[J]. Eur Heart J, 2017,38(32): 2459-2472.
[7] Catapano AL,Graham I,De Backer G,et al.2016 ESC/EAS Guide-lines for the management of dyslipidaemias[J].Kardiol Pol,2016,74( 11): 1234-1318.
[8] 中国成人血脂异常防治指南修订联合委员会.中国成人血脂异常防治指南(2016年修订版)[J].中华全科医师杂志,2017,16(1):15-35.
[9] 海峡两岸医药卫生交流协会老年医学专业委员会.≥75岁老年患者血脂异常管理的专家共识[J].中国心血管杂志,2020,25(3):201-209.
[10] Arnett DK,Blumenthal Rs,Albert MA,et al.2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary:a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines[J].J Am coll cardiol.2019,74(10):1376-1414.
[11] Go AS,MoZAFFARIAN D,RoGER VL,et a1.American Heart Association Statistics Committee and Stroke Statistics Subcommittee.Heart disease and stroke statistics·2013update:a report from the American Heart Association[J].Circulation,2014,1 29(3):e28-e292.
[12] 胡盛寿,高润霖,刘力生,等.《中国心血管病报告2018》概要[J].中国循环杂志,2019,34(3):209-220.
[13] Hu SS, Gao RL, Liu LS, et al.Summary of the 2018 report on cardiovascular diseases inChina[J]. Chin Circul J, 2019, 34(3): 209-220.
[14] Du LP, Cheng ZW, Zhang YX, et al.The impact of medication adherence on clinical outcomes of coronary artery disease: A meta-analysis[J]. Eur J Prev Cardiol, 2017, 24(9): 962-970.
[15] Zhao SP.The clinical application of pitavastatin: evidence of efficacy and safety in East Asian population[J]. Chin J Intern Med, 2018, 57(5): 374-377.
[16] Barrios V, Escobar C.Clinical benefits of pitavastatin: focus on patients with diabetes or at risk of developing diabetes[J]. Futur Cardiol, 2016,12(4): 449-466.
[17] Hoeke G,Wang YN,Van Dam AD,et al.Atorvastatin accelerates clearance of lipoprotein remnants generated by activated brown fat to further reduce hypercholesterolemia and atherosclerosis[J].Atherosclerosis,2017,267:116-126.
[18] Carmena R, Betteridge DJ.Diabetogenic action of statins:mechanisms[J]. Curr Atheroscler Rep, 2019, 21(6): 23.
[19] Chan P, Shao L, Tomlinson B, et al.An evaluation of pitavastatin for the treatment of hypercholesterolemia[J]. Expert Opin Pharmacother, 2019, 20(1): 103-113.
[20] Marellic,Lamarif,Rainteau D,et al.Plasma oxysterols:biomarkers for diagnosis and reatment in spastic paraplegia type 5[J].Brain,2018,141(1):72-84.
[21] Vikulova DN, Grubisic M, Zhao YS, et al.Premature atherosclerotic ardiovascular disease: trends in incidence, risk factors, and ex-related differences, 2000 to 2016[J]. J Am Heart Assoc, 2019, 8(14): 12178.